Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Alkermes Plc

ALKS
Current price
24.29 USD +0.1 USD (+0.41%)
Last closed 24.14 USD
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Exchange NASDAQ
Capitalization 4 053 539 328 USD
Yield for 12 month -4.78 %
Week
Month
Year
ALKS
21.11.2021 - 28.11.2021

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in the fields of neuroscience and oncology in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products focused on alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of product candidates in development for neurological disorders and cancer. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence, and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and nemvaleukin alfa, an engineered fusion protein to expand tumor-killing immune cells and to avoid the activation of immunosuppressive cells. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland. Address: Connaught House, Dublin, Ireland, 4

Analytics

WallStreet Target Price

33.09 USD

P/E ratio

19.5887

Dividend Yield

2.59 %

Current Year

+1 111 795 000 USD

Last Year

+1 173 751 000 USD

Current Quarter

+380 938 000 USD

Last Quarter

+617 397 000 USD

Current Year

+893 687 000 USD

Last Year

+569 838 000 USD

Current Quarter

+319 429 000 USD

Last Quarter

+453 349 000 USD

Key Figures ALKS

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA 297 028 000 USD
Operating Margin TTM 13.09 %
PE Ratio 19.5887
Return On Assets TTM 6.54 %
PEG Ratio -1057.29
Return On Equity TTM 17.91 %
Wall Street Target Price 33.09 USD
Revenue TTM 1 590 604 032 USD
Book Value 8.13 USD
Revenue Per Share TTM 9.62 USD
Dividend Share
Quarterly Revenue Growth YOY 51 %
Dividend Yield 2.59 %
Gross Profit TTM 893 687 000 USD
Earnings Share 1.24 USD
Diluted Eps TTM 1.24 USD
Most Recent Quarter III 2023
Quarterly Earnings Growth YOY
Profit Margin 13.5 %

Dividend Analytics ALKS

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History ALKS

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield 2.59 %
Last Split Factor 2:1
Payout Ratio
Last Split Date 15.05.2000
Dividend Date

Stock Valuation ALKS

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE 19.5887
Forward PE 13.8504
Enterprise Value Revenue 2.2283
Price Sales TTM 2.5484
Enterprise Value EBITDA 11.2384
Price Book MRQ 2.9866

Financials ALKS

1 year
3 years
5 years
10 years
Results 2019 Dynamics

Technical indicators ALKS

For 52 weeks

20.46 USD 31.34 USD
50 Day MA 25.86 USD
Shares Short Prior Month 7 962 617
200 Day MA 28.42 USD
Short Ratio 3.54
Shares Short 7 958 062
Short Percent 5.44 %